Sichuan Biokin Pharmaceutical (SHA:688506) received the approval of China's National Medical Products Administration to conduct clinical trials on injection BL-M24D1 (ADC), according to a Shanghai bourse filing on Wednesday.
The drug will be tested as a treatment for patients with relapsed or refractory hematologic malignancies and advanced solid tumors.
The company's shares slipped less than 2% during morning trade.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.